SCHEMBL19736992

SCHEMBL19736992

CC(C)c1ccc(OCc2ccccc2F)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
PKM P14618 2/20 0.49
MCL1 Q07820 1/20 0.46
FNTA P49354 1/20 0.44
FNTB P49356 1/20 0.44
LMNA P02545 4/20 0.43
MRGPRX4 Q96LA9 3/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPK1 P28482 1/20 0.43
PDK2 Q15119 1/20 0.42
CLCN2 P51788 1/20 0.42
CD274 Q9NZQ7 1/20 0.41
PTGER1 P34995 1/20 0.41
HTR1A P08908 1/20 0.41
SLC6A2 P23975 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17858627 0.81 MAPT (0.60) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL27298972 0.80 PDK2 (0.40) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL10172543 0.80 NPC1 (0.52) MAPTSMN1; SMN2NPC1RAB9AMRGPRX4
SCHEMBL15132934 0.79 MAOB (0.59) SMN1; SMN2NPC1RAB9APKMFNTA
SCHEMBL19736986 0.79 RAB9A (0.57) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL3319862 0.78 MAPT (0.60) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL19728981 0.78 SMN1; SMN2 (0.56) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL21017995 0.77 CD274 (0.66) CD274
SCHEMBL13900992 0.77 EGFR (0.53) MRGPRX4KDM4E
SCHEMBL27299220 0.75 PDK2 (0.42) MAPTSMN1; SMN2NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10206924-B2 Small molecule inhibitors of EGFR and PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-02-19 US disclosed
US-20170360788-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10206924-B2 Small molecule inhibitors of EGFR and PI3K EGFR, ERBB2, ERBB3 MAPT 3279/4885SMN1; SMN2 4865/4885NPC1 2896/4885
US-20170360788-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K EGFR, ERBB2, ERBB3 MAPT 3279/4885SMN1; SMN2 4865/4885NPC1 2896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.